On 10 July, Eisai announced the official opening of its Center for Genetics Guided Dementia Discovery (G2D2) in Cambridge, Massachusetts. Research at G2D2 will focus on the brain’s immune system, aiming to discover new drug targets beyond tau and beta amyloid. Researchers at G2D2 hope to build on recent advances in human genetics, data science and precision chemistry to develop targeted therapies for Alzheimer’s disease. Embedded within G2D2, the Eisai Incubator for NeuroDiscovery (e-IND) aims to provide space for spin-out companies hoping to develop innovative therapeutics for neurodegenerative disease.
Eisai officially opens its Center for Genetics Guided Dementia Discovery in Cambridge, Massachusetts
10/07/2019
